论文部分内容阅读
探讨不同亚型α干扰素(IFNα-2a、IFNα-2b)治疗慢性乙型肝炎的疗效差异。110例慢性乙型肝炎(CHB)患者被随机分为IFNα-2a治疗组(52例)和IFNα-2b治疗组(58例)。IFNα-2a治疗组采用IFNα-2a(因特芬)每日3MU肌注,IFNα-2b治疗组采用IFNα-2b(隆化诺)每日3MU肌注,30天后改隔日3MU肌注,疗程6月。观察两组用药3月、6月后血清ALT复常率、HBeAg阴转率、HBV-DNA阴转率和治疗反应率。ALT复常率两组无明显差异(P>0.05)。HBeAg阴转率:IFNα-2b治疗组(51.7％、67.2％),明显优于IFNα-2a治疗组(32.7％、44.2％),两组差异明显(P<0.05)。HBV DNA阴转率:6月后IFNα-2b治疗组(58.6％),明显优于IFNα-2a治疗组(34.6％),两组差异明显(P<0.05)。治疗后完全反应率:IFNα-2b治疗组(46.6％),明显优于IFNα-2a治疗组(21.2％),两组间有极显著差异(P<0.01)。干扰素α-2b亚型治疗慢性乙型肝炎疗效明显优于干扰素α-2a亚型。
To investigate the different efficacy of interferon-alpha (IFNα-2a, IFNα-2b) in the treatment of chronic hepatitis B patients. One hundred and ten patients with chronic hepatitis B (CHB) were randomly divided into IFNα-2a treatment group (52 cases) and IFNα-2b treatment group (58 cases). IFNα-2a treatment group with daily intramuscular IFNα-2a (Intuven) intramuscular injection, IFNα-2b treatment group with IFNα-2b (Long promise promise) daily 3MU intramuscular injection, 3MU intramuscular injection after 30 days, treatment 6 month. The two groups were observed in March, 6 months after the serum ALT normalization rate, HBeAg negative conversion rate, HBV-DNA negative conversion rate and response rate. ALT normalization rate was no significant difference between the two groups (P> 0.05). HBeAg negative rate: IFNα-2b treatment group (51.7%, 67.2%), significantly better than IFNα-2a treatment group (32.7%, 44.2%), the difference was significant between the two groups (P <0.05). The negative rate of HBV DNA in IFNα-2b treatment group (58.6%) after 6 months was significantly better than that in IFNα-2a treatment group (34.6%), with significant difference between the two groups (P <0.05). The complete response rate after treatment was significantly higher in IFNα-2b treatment group (46.6%) than in IFNα-2a treatment group (21.2%), with significant difference between the two groups (P <0.01). Interferon α-2b subtype of treatment of chronic hepatitis B was significantly better than interferon α-2a subtype.